Publikationsserver
Persistence in allergen immunotherapy: A longitudinal, prescription data‐based real‐world analysis
Introduction: Allergic rhinitis (AR) is a widespread disease with increasing prevalence in developed countries. The only treatment that tackles the underlying causes is allergen immunotherapy (AIT). This treatment is performed through two application routes, the subcutaneous immunotherapy (SCIT)...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | İngilizce |
| Baskı/Yayın Bilgisi: |
Philipps-Universität Marburg
2023
|
| Konular: | |
| Online Erişim: | PDF Tam Metin |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
| Özet: | Introduction: Allergic rhinitis (AR) is a widespread disease with increasing prevalence
in developed countries. The only treatment that tackles the underlying causes
is allergen immunotherapy (AIT). This treatment is performed through two application
routes, the subcutaneous immunotherapy (SCIT) or the sublingual immunotherapy
(SLIT). However, persistence during the long course of treatment over
3 years is key for the efficacy of this treatment option. The impaired adherence
significantly impacts public health resources. The aim of this study was to assess the
persistence of AIT for both application routes.
Methods: IQVIATM LRx was used to identify patients starting AIT between 2009
and 2018 with grass pollen (GP), early flowering tree pollen (EFTP) and house dust
mite (HDM) allergens. Patients were classified within each allergen category by AIT
groups (subcutaneous depigmented polymerised allergen AIT [dSCIT], other subcutaneous
AIT [oSCIT] and SLIT) and age (5‐11 years, 12‐17 years, 18+ years).
Furthermore, they were followed up for up to 3 years until the cessation of treatment.
Patients, who were still on treatment after 3 years were deemed to be
censored. Kaplan‐Meier curves of persistence were generated and compared by
log‐rank tests.
Results: The number of patients included in the three allergen categories was
38,717 GP, 23,183 EFTP, and 41,728 HDM AIT. In all allergen categories and for
any product group, patient persistence decreased with increasing age class with the
difference between 5‐11 years and 12‐17 years greater than between the latter and
18+ years. The percentage of patients completing the first year of AIT was low,
particularly for SLIT where 22.2%–27.1% of patients remained persistent after
12 months. The equivalent figures for dSCIT were 52.0%–64.1% and for oSCIT
38.3%–50.3%.
Conclusion: Persistence in AIT in AR was low in this retrospective prescriptionbased
database and was clearly linked to patient age and application route. |
|---|---|
| Diğer Bilgileri: | Gefördert durch den Open-Access-Publikationsfonds der UB Marburg. |
| DOI: | 10.1002/clt2.12245 |